NewSquare Capital’s Ligand Pharmaceuticals LGND Stock Holding History

NewSquare Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20	Closed	-$1.44K	–	758
2023 Q2	$1.44K	Hold	20	–	–	﹤0.01%	563
2023 Q1	$1.47K	Hold	20	–	–	﹤0.01%	604
2022 Q4	$1.34K	Buy	+20	New	+$1.3K	﹤0.01%	541
2018 Q4	–	Sell	-1,379	Closed	-$236K	–	345
2018 Q3	$236K	Buy	+1,379	New	+$208K	0.04%	111
2016 Q4	–	Sell	-38	Closed	-$2K	–	393
2016 Q3	$2K	Buy	+38	New	+$2.79K	﹤0.01%	449

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NewSquare Capital's LGND Position: Q3 2023 in Review

NewSquare Capital sold out of Ligand Pharmaceuticals (LGND) in Q3 2023, closing a stake of 20 shares — an estimated $1.44K sold.

NewSquare Capital first reported a position in LGND in Q3 2016 and held it in 5 quarters. The position peaked at $236K in Q3 2018. 196 funds tracked by Wall St. Rank hold LGND as of Q3 2023.

NewSquare Capital reported no remaining Ligand Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
NewSquare Capital sold 20 Ligand Pharmaceuticals shares in Q3 2023, an estimated $1.44K.
NewSquare Capital first reported a position in Ligand Pharmaceuticals in Q3 2016 and held it in 5 quarters.
NewSquare Capital's Ligand Pharmaceuticals position peaked at $236K in Q3 2018.
196 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.